Abstract:Targeting PD-L1 via monospecific antibodies has shown durable clinical benefits and long-term remissions where patients exhibit no clinical cancer signs for many years after treatment. However, the durable clinical benefits and long-term remissions by anti-PD-L1 monotherapy have been limited to a small fraction of patients with certain cancer types. Targeting PD-L1 via bispecific antibodies (referred to as anti-PD-L1-based bsAbs) which can simultaneously bind to both co-inhibitory and co-stimulatory molecules may increase the durable antitumor responses in patients who would not benefit from PD-L1 monotherapy. A growing number of anti-PD-L1-based bsAbs have been developed to fight against this deadly disease. This review summarizes recent advances of anti-PD-L1-based bsAbs for cancer immunotherapy in patents and literatures, and discusses their anti-tumor efficacies in vitro and in vivo. Over 50 anti-PD-L1-based bsAbs targeting both co-inhibitory and co-stimulatory molecules have been investigated in biological testing or in clinical trials since 2017. At least eleven proteins, such as CTLA-4, LAG-3, PD-1, PD-L2, TIM-3, TIGIT, CD28, CD27, OX40, CD137, and ICOS, are involved in these investigations. Twenty-two anti-PD-L1-based bsAbs are being evaluated to treat various advanced cancers in clinical trials, wherein the indications include NSCLC, SNSCLC, SCLC, PDA, MBNHL, SCCHN, UC, EC, TNBC, CC, and some other malignancies. The released data from clinical trials indicated that most of the anti-PD-L1-based bsAbs were well-tolerated and showed promising antitumor efficacy in patients with advanced solid tumors. However, since the approved and investigational bsAbs have shown much more significant adverse reactions compared to PD-L1 monospecific antibodies, anti-PD-L1-based bsAbs may be further optimized via molecular structure modification to avoid or reduce these adverse reactions.

Bispecific Antibodies, Immune Checkpoint Inhibitors, and Antibody−Drug Conjugates Directing Antitumor Immune Responses: Challenges and Prospects

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling

Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison

Immune checkpoint inhibitors: breakthroughs in cancer treatment

Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy

Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment

Therapeutic Antibodies and Immunologic Conjugates

Bispecific Antibodies Targeting Immunomodulator Y Checkpoints for Cancer Therapy

Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy

Bispecific therapeutics: a state-of-the-art review on the combination of immune checkpoint ‎inhibition with costimulatory and non-checkpoint targeted therapy

Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy

Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy.

Immune Checkpoint Inhibitors Combined with Targeted Therapy: the Recent Advances and Future Potentials

Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy

Better safe than sorry: dual targeting antibodies for cancer immunotherapy

Anti-PD-L1-Based Bispecific Antibodies Targeting Co-Inhibitory and Co-Stimulatory Molecules for Cancer Immunotherapy

Current landscape and future directions of bispecific antibodies in cancer immunotherapy

Bi-specific antibody engagers for cancer immunotherapy

Advances in the study of CD47‐based bispecific antibody in cancer immunotherapy